B. Engels

发表

The tumor-associated antigen EBAG9 negatively regulates the cytolytic capacity of mouse CD8+ T cells.

B. Dörken, J. Wolf, C. Rüder, 2009, The Journal of clinical investigation.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

C. June, B. Engels, A. Hemminki, 2018, JCI insight.

T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy

T. Blankenstein, B. Engels, W. Uckert, 2010, Clinical Cancer Research.

B. Engels, W. Uckert, A. Thrasher, 2005 .

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

Yong Gu Lee, Nathan H. Roy, S. Grupp, 2021, Nature Network Boston.

Spleen cells from young but not old immunized mice eradicate large established cancers

J. Sidney, A. Sette, R. Weichselbaum, 2012, Clinical Cancer Research.

transduced human T cells Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene

B. Engels, A. Thrasher, D. Hart, 2013 .

Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.

T. Blankenstein, B. Engels, W. Uckert, 2005, Human gene therapy.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation

Yusuke Nakamura, R. Weichselbaum, B. Engels, 2015, Clinical Cancer Research.

MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR

D. Kranz, B. Engels, E. Roy, 2013, Cancer Immunology, Immunotherapy.

IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner

B. Engels, H. Schreiber, B. Jabri, 2013, Proceedings of the National Academy of Sciences.

CY15, a malignant histiocytic tumor that is phenotypically similar to immature dendritic cells.

T. Blankenstein, B. Engels, B. Erdmann, 2005, Cancer research.

Densely granulated murine NK cells eradicate large solid tumors.

B. Engels, H. Schreiber, A. Arina, 2012, Cancer research.

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

Na Li, Andreas Loew, Gabriela Plesa, 2015, Science Translational Medicine.

Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity.

D. Kranz, B. Engels, H. Schreiber, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Alexandria P. Cogdill, C. June, M. Feldman, 2016, Immunity.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

R. Weichselbaum, Hua Yu, N. Hübner, 2017, Nature.

Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer

D. Munn, R. Hoffman, B. Engels, 2013, Cancer Immunology Research.

The Antitumorigenic Response of Neural Precursors Depends on Subventricular Proliferation and Age

L. Kaczmarek, H. Kettenmann, G. Kempermann, 2008, Stem cells.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

John Sidney, Alessandro Sette, David M Kranz, 2013, Cancer cell.

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer

Jianhua Huang, Hans Schreiber, David W Piston, 2013, Oncoimmunology.

Retroviral vectors for high-level transgene expression in T lymphocytes.

T. Blankenstein, B. Engels, W. Uckert, 2003, Human gene therapy.

Designer T cells by T cell receptor replacement

M. Heemskerk, T. Blankenstein, B. Engels, 2006, European journal of immunology.

Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.

B. Engels, W. Uckert, 2007, Molecular aspects of medicine.

Targeting stroma to treat cancers.

B. Engels, H. Schreiber, D. Rowley, 2012, Seminars in cancer biology.

Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains

Thomas M. Schmitt, B. Baker, P. Greenberg, 2011, Gene Therapy.

Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette

B. Engels, W. Uckert, M. Leisegang, 2008, Journal of Molecular Medicine.

Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette

B. Engels, W. Uckert, M. Leisegang, 2008, Journal of Molecular Medicine.

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

J. Briones, I. Flinn, U. Jaeger, 2021, Blood.

Ibrutinib before Apheresis May Improve Tisagenlecleucel Manufacturing in Relapsed/Refractory Adult Diffuse Large B-Cell Lymphoma: Initial Results from a Phase 1b Study

B. Engels, S. Schuster, F. Locke, 2020 .

Design of T cell receptor libraries with diverse binding properties to examine adoptive T cell responses

D. Kranz, B. Engels, E. Roy, 2012, Gene Therapy.

Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.

D. Kranz, B. Engels, H. Schreiber, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Tar geting the Cancer-AssociatedTn-Glycoformof theMembraneMucinMUC 1 Control Adenocarcinoma Highlights

David M. Kranz, Jennifer D. Stone, Brian Keith, 2016 .

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Nathan H. Roy, S. Grupp, C. June, 2019, Blood.

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

S. Grupp, D. Porter, C. June, 2017 .

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

G. Wertheim, S. Grupp, B. Engels, 2022, Blood.

Two Cases of Severe Pulmonary Toxicity from Highly Active Mesothelin-Directed CAR T Cells.

Ryan J. Golden, C. June, Xiaojun Liu, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy

Jennifer Yang, B. Engels, J. Brogdon, 2021, Blood.

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Shannon R. McCurdy, D. Porter, B. Levine, 2021, Blood.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

J. Briones, I. Flinn, D. Blaise, 2023, Cancer discovery.

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.

B. Engels, W. Uckert, A. Thrasher, 2005, Blood.

T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy

T. Blankenstein, B. Engels, W. Uckert, 2010, Clinical Cancer Research.